LSK Global PS, Digital Innovation at Korea’s Leading, Integrated CRO
The remarkable advancement and growth of Korea’s medical technology and related services have been accompanied by a steady increase in requested services of Contract Research Organizations (CROs). According to Fortune Business Insights, the worldwide e-signature market is expected to grow from USD 879 million in 2018 to USD 6.1 billion in 2026. Amidst this growth trend, LSK Global PS is considered one of the CROs to watch carefully.
LSK Global PS was founded in March 2000, the early days of new drug development in Korea’s pharmaceutical industry, and provides support for all areas from development of new pharmaceuticals, to consulting and clinical studies including pre-approval Phase I through Phase III trials, investigator-initiated research, post-approval Phase IV trials, post-marketing surveillance (PMS), and observational studies. Since its establishment (as of Dec. 2019), LSK Global PS has conducted 1,150 clinical trials and in the process became Korea’s first CRO to carry out a large-scale, international clinical trial of an anti-cancer drug involving 95 testing sites in 12 countries, including the US and others across Europe and Asia.
As LSK Global PS continues to strengthen its leading position in the growing CRO market, the company is also moving quickly on digital innovation of its work processes in response to the contactless era brought about by Covid-19. A key task of major importance for LSK Global PS was the introduction of an e-signature solution, as in every stage of the CRO’s work process, from the commission and execution of a clinical study to the finding of results, rapid confirmation and safe approval among the parties concerned are keenly necessary.
According to Clinical Data Management HQ Executive Director Lee Jeong-Min, “The healthcare field, like other industries, has been experiencing an increasing demand for e-signatures, and as a global company, we could no longer put off its implementation. At just the right time, we came across Adobe Sign, which turned out to be the optimum, all-around solution for us.”